ad

Windlas Biotech Q2 Results FY27: PAT Rises 1.4% to Rs 18.05 Cr, Revenue Rs 263.91 Cr

5 Nov 2026 • 8:51 pm

Windlas Biotech Q2 Results FY27: PAT Rises 1.4% to Rs 18.05 Cr, Revenue Rs 263.91 Cr

Quick Answer

Windlas Biotech Q2 Results FY27 were declared on 5 November 2026 on a standalone basis. The quarterly results show revenue of Rs 263.91 Cr against Rs 222.4 Cr in the same quarter last year, a YoY growth of 18.66%. Net profit was Rs 18.05 Cr against Rs 17.8 Cr, up 1.4%, while Operating Profit stood at Rs 29.37 Cr.

Windlas Biotech Ltd (WINDLAS) Q2 Results FY27 announced on 5 November 2026, covering the company's financial performance for the July to September quarter. The results date brought standalone revenue of Rs 263.91 Cr and PAT of Rs 18.05 Cr, and Windlas Biotech Q2 Results FY27 are shown on the standalone results basis against the July to September 2025 quarter.

This Windlas Biotech Q2 Results results analysis covers the financial highlights, the business factors, the outlook and the risks. The section below places revenue, Operating Profit and net profit next to the figures for the same quarter a year earlier.

Click Here – Get Free Investment Predictions

Windlas Biotech Q2 Results FY27: Financial Highlights

Metric Q2 FY27 (Sep 26) Q2 FY26 (Sep 25) YoY Change
Revenue Rs 263.91 Cr Rs 222.4 Cr +18.66% YoY
Operating Profit Rs 29.37 Cr Rs 28.56 Cr +2.84% YoY
Net Profit (PAT) Rs 18.05 Cr Rs 17.8 Cr +1.4% YoY

Source: company filing for Windlas Biotech Q2 Results FY27, 5 November 2026. Figures in Rs Crore, Standalone basis.

Key Takeaways from Windlas Biotech Q2 Results: What Stands Out

  • Revenue of Rs 263.91 Cr was reported for the quarter, against Rs 222.4 Cr a year earlier, which is a YoY growth of 18.66%.
  • Net profit of Rs 18.05 Cr compares with Rs 17.8 Cr in the same quarter last year, a rise of 1.4% year on year.
  • Operating Profit of Rs 29.37 Cr compares with Rs 28.56 Cr a year earlier, a YoY growth of 2.84% on the standalone results basis.
  • Windlas Biotech Q2 Results FY27 show all three headline lines higher than in the July to September 2025 quarter.
  • The risk list in the filing data covers the narrower margin and the return ratios, and the performance analysis below comes first.

Windlas Biotech Q2 Results FY27: Performance Analysis

Standalone figures show that revenue, Operating Profit and net profit all moved higher year on year in the quarter ended September 2026. Revenue rose 18.66% to Rs 263.91 Cr, Operating Profit rose 2.84% to Rs 29.37 Cr and net profit rose 1.4% to Rs 18.05 Cr, all on a standalone basis.

In this Windlas Biotech Q2 Results FY27 results analysis, revenue grew much faster than the profit lines, since the 18.66% rise compares with a 2.84% rise in Operating Profit and a 1.4% rise in net profit. The supplied data confirms these figures but does not establish a specific cause for the gap.

For the Windlas Biotech Q2 Results quarter, the absolute figures are also visible: revenue is higher by the difference between Rs 222.4 Cr and Rs 263.91 Cr, while net profit moved from Rs 17.8 Cr to Rs 18.05 Cr. Investors will next follow the quarterly results disclosures, which is where the business factors come in.

Check the Univest Screener for live results data

Key Business Factors This Quarter

Revenue Growth – The business factors behind the quarterly results begin with the top line. Revenue grew 18.7% year on year to Rs 263.91 Cr in the latest quarter, from Rs 222.4 Cr in the same quarter a year earlier, on a standalone basis.

Net Profit Growth – Net profit rose 1.4% year on year to Rs 18.05 Cr, compared with Rs 17.8 Cr a year earlier. In Windlas Biotech Q2 Results FY27, this profit line grew by a smaller percentage than revenue, which links the bottom line to the sales figure above.

Consecutive Revenue Growth – Revenue has risen in each of the last 4 quarters. The latest figure of Rs 263.91 Cr therefore continues a run of sequential increases reported in the quarterly results data.

FY27 Outlook After Windlas Biotech Q2 Results

The business factors lead into the outlook, where the results analysis rests on the figures declared for the quarter. The company reported net profit of Rs 18.05 Cr for July to September 2026, and the full FY27 picture will depend on the numbers reported in the quarters that follow.

In Windlas Biotech Q2 Results FY27, the YoY direction is higher on all three lines, so the next standalone filings will show whether that pattern holds. Investors can track revenue, Operating Profit and net profit on Univest, and the risks below show what to watch alongside them.

Key Risks to Watch After Windlas Biotech Q2 Results FY27

Narrower Net Profit Margin

Net profit margin narrowed to 6.8% from 8.0% in the comparison quarter. After Windlas Biotech Q2 Results FY27, this margin remains a number investors can follow in later filings, since revenue grew faster than net profit.

Return on Capital Employed

Return on capital employed declined to 16.06% in FY26 from 17.12% in FY25. This is a full year measure, so it sits apart from the quarter's YoY growth but remains part of the picture investors weigh.

Return on Equity

Return on equity of 12.52% in FY26 is below 15%. Together with the return on capital employed, it frames the conclusion that investors draw from the quarterly results.

Download the Univest iOS App or Univest Android App to track quarterly results as they are declared.

Conclusion

Windlas Biotech Q2 Results FY27 show standalone revenue of Rs 263.91 Cr, Operating Profit of Rs 29.37 Cr and net profit of Rs 18.05 Cr, all higher year on year. These quarterly results come with margin and return risks that investors can follow through the standalone results on Univest. Consult a SEBI-registered advisor before acting on this Windlas Biotech Q2 Results analysis.

Disclaimer: Data and figures in this article are sourced from publicly available information. These may or may not be accurate. Please verify all data with the official NSE (nseindia.com) and BSE (bseindia.com) websites before making any investment decision. Investments in securities are subject to market risk. This content is for educational purposes only and is not investment advice. Research Analyst: Uniresearch Global Pvt. Ltd., SEBI Registration No. INH000013776.

Frequently Asked Questions on Windlas Biotech Q2 Results FY27

What are Windlas Biotech Q2 Results FY27?

Ans. Windlas Biotech Q2 Results FY27 cover the July to September 2026 quarter on a standalone basis, with revenue of Rs 263.91 Cr. The Financial Highlights table compares each line with the same quarter last year.

What is the results date for Windlas Biotech Q2 Results FY27?

Ans. The results date for Windlas Biotech Q2 Results FY27 is 5 November 2026, when the company declared its numbers for the quarter. This date appears in the Quick Answer and the opening paragraphs.

What revenue was reported in Windlas Biotech Q2 Results FY27?

Ans. Windlas Biotech reported revenue of Rs 263.91 Cr in the quarter, compared with Rs 222.4 Cr a year earlier. This comparison is shown in the Financial Highlights table and the Performance Analysis section.

What net profit was reported in Windlas Biotech Q2 Results FY27?

Ans. Net profit in the quarter was Rs 18.05 Cr, against Rs 17.8 Cr in the same quarter last year. The Key Takeaways section lists this figure alongside revenue and Operating Profit for quick reading.

How much YoY growth did revenue show in Windlas Biotech Q2 Results FY27?

Ans. Revenue showed YoY growth of 18.66% in the quarter, rising from Rs 222.4 Cr to Rs 263.91 Cr. The Performance Analysis section compares this with the 1.4% rise in net profit.

Did net profit rise or fall in Windlas Biotech Q2 Results?

Ans. Net profit rose in the quarter by 1.4% year on year, from Rs 17.8 Cr to Rs 18.05 Cr. The Key Business Factors section explains how this compares with the growth in revenue.

What was the Operating Profit in Windlas Biotech Q2 Results FY27?

Ans. Operating Profit was Rs 29.37 Cr in the quarter, up 2.84% from Rs 28.56 Cr a year earlier. This line is covered in the Performance Analysis section alongside revenue and net profit.

Are Windlas Biotech Q2 Results consolidated results or standalone results?

Ans. The results are standalone results, covering Windlas Biotech as a single company for the quarter. This basis is stated in the Quick Answer and again in the Conclusion section.

What business factors shaped Windlas Biotech Q2 Results FY27?

Ans. Revenue growth of 18.7%, net profit growth of 1.4% and four straight quarters of rising revenue are the factors reported for the quarter. The Key Business Factors section sets each one out.

What are the key risks after Windlas Biotech Q2 Results FY27?

Ans. The risks listed are a net profit margin of 6.8%, return on capital employed of 16.06% and return on equity of 12.52% in FY26. The Key Risks section describes each of them.

What is the outlook after Windlas Biotech Q2 Results?

Ans. The FY27 outlook depends on the figures reported in the coming quarters, since the quarter showed higher revenue and profit year on year. The Outlook section explains what investors can track.

Where can I find the complete Windlas Biotech Q2 Results FY27 data?

Ans. The complete data sits in the Financial Highlights table near the top of this article, which compares each line with the same quarter last year. The Univest app also carries the standalone results.


Recent Articles

Note: This blog is for information purpose only. Investments and trading are subject to market risks, read all scheme related documents carefully.

Reviews

user-review-1
user-review-2
user-review-3
user-review-4
user-review-5

RESEARCH ANALYST

Get SEBI Registered
advice on the stocks
trending today.

Get 3 FREE Trade Ideas

+91
for Startups Accelerator 2024

for Startups Accelerator 2024

Trusted by 1Cr Indians

Trusted by 1Cr Indians

Awarded No.1 by Economic Times

Awarded No.1 by Economic Times

GET THE APP

Join 1Cr users today.

SEBI Registered Analyst-backed Picks. Free Demat. One App

  • Free Demat account in under 5 minutes
  • Live market data — Nifty, Sensex, sector insights
  • SEBI Registered analyst-backed stock picks
Get it on Google PlayDownload on the App Store
Stocks:
All|a|b|c|d|e|f|g|h|i|j|k|l|m|n|o|p|q|r|s|t|u|v|w|x|y|z

Copyright 2026 Univest. All rights reserved.
Designed with ❤️ in India

arrow down